Depression and anxiety disorders in patients with multiple sclerosis: association with neurodegeneration and neurofilaments

Autor(es)

Tauil, C. B. ^[1] ; Rocha-Lima, A. D. ^[2] ; Ferrari, B. B. ^[2] ; Silva, F. M. ^[3] ; Machado, L. A. ^[3] ; Ramari, C. ^[1] ; Brandao, C. O. ^[2] ; dos Santos, L. M. B. ^[2] ; dos Santos-Neto, L. L. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Brasilia, Dept Ciencias Med, Brasilia, DF - Brazil

^[2] Univ Estadual Campinas, Inst Biol, Dept Genet Evolucao Microbiol & Imunol, Unidade Neuroimunol, Campinas, SP - Brazil

^[3] Hosp Base Brasilia, Dept Psicol, Brasilia, DF - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Brazilian Journal of Medical and Biological Research; v. 54, n. 3 2021.
• Citações Web of Science: 0

Resumo

There is increasing evidence that neurofilament light chain (NF-L) can be considered as a biomarker for neuro-axonal damage. This polypeptide can be released into the cerebrospinal fluid (CSF) and the blood, where it can be quantified. The concentration of NF-L is elevated in patients with multiple sclerosis (MS) and psychiatric disorders. We aimed to investigate the NF-L levels in the CSF from treated MS patients and the relationship with depression or anxiety. The study involved three groups: control group (individuals without inflammation), the relapse-remitting multiple sclerosis (RRMS)-untreated group, and the RRMS-Fingo group (RRMS patients who were treated with fingolimod). MS disability was assessed by the Expanded Disability Status Scale, and depression and anxiety were evaluated by a neuropsychologist, using the Hospital Anxiety and Depression Scale, the Beck Depression Inventory-II, and the Beck Anxiety Inventory. Individual CSF samples were collected to measure NF-L levels. The results of the statistical analysis on levels of NF-L in the CSF of control subjects, RRMS-untreated patients, and RRMS-Fingo patients were significant. The relationship between depression and anxiety in RRMS-Fingo patients and NF-L levels was not statistically significant. In conclusion, MS events such as anxiety and depression appear to contribute to the onset of clinical relapses, subclinical cases, and neurodegeneration. (AU)

• Processo FAPESP: 14/26431-0 - Esclerose múltipla, estudo clínico, neuropsicológico, imunológico, biomarcadores e novas drogas modificadoras da doença
• Beneficiário: Leonilda Maria Barbosa dos Santos
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 16/17404-5 - Estudo das subpopulações de linfócitos b no sangue periférico de pacientes com esclerose múltipla primária progressiva
• Beneficiário: Leonilda Maria Barbosa dos Santos
• Modalidade de apoio: Auxílio à Pesquisa - Regular